Two different answers to the same hip problem

'I've been told I have a cartilage defect in my hip — do I need surgery, or can it be treated with an injection?' For many patients, the honest answer is: it depends on the defect, not on a simple ranking of one treatment over the other.

AMIC (Autologous Matrix-Induced Chondrogenesis) and ChondroFiller injection both address focal hip cartilage damage in younger patients who still have good overall joint health. What separates them is how they work and where they are delivered. AMIC is a theatre-based procedure that rebuilds the cartilage from the bone upward. ChondroFiller injection places a regenerative collagen scaffold into the defect via an ultrasound-guided outpatient injection — no operating theatre, no general anaesthetic.

Neither approach suits everyone, and the choice is not a matter of one being superior to the other. Defect size, location, depth, and each patient's circumstances and recovery expectations all feed into the decision. Lincolnshire Hip offers both pathways; the right starting point is a hip assessment to confirm what the defect looks like and which route fits.

What AMIC involves and who it is for

AMIC is built around a straightforward biological principle: if you give the body access to its own repair cells and a structure to guide them, it can fill a cartilage defect more durably than the defect could heal on its own.

The procedure has two steps, carried out as a single operation in an operating theatre under general or spinal anaesthesia. First, the surgeon makes small perforations into the subchondral bone beneath the damaged cartilage — a technique called microfracture — releasing stem cells and growth factors from the bone marrow below. Second, a thin bioresorbable collagen I/III membrane is pressed over the defect to hold the marrow clot in place and scaffold the incoming cells as they migrate upward into the lesion. Without that membrane, the clot tends to be unstable and typically produces fibrocartilage — a weaker, more brittle tissue than healthy hyaline cartilage. The scaffold shifts the balance towards hyaline-like repair, which is why AMIC consistently outperforms microfracture alone in published series.

Access is gained arthroscopically in most cases; some defect locations require surgical hip dislocation depending on anatomy and surgeon preference.

Typical candidates are active patients under 50 with an isolated, bordered focal defect — commonly in the 3–4 cm² range, though the threshold for indication begins at ≥2 cm² — and well-preserved joint space. In published hip cohorts the weighted mean age is around 35.8 years, and the lesion is most often linked to femoroacetabular impingement (FAI) morphology. Surrounding cartilage must be healthy; diffuse chondral loss or established osteoarthritis places the joint outside the procedure's range of benefit.

What the ChondroFiller injection involves and who it suits

Delivered under local anaesthesia in an outpatient clinic, the ChondroFiller injection uses ultrasound guidance to place a cell-free collagen type I hydrogel directly into the hip cartilage defect. The gel sets within the joint environment, forming a scaffold over the defect surface — no bone perforation, no marrow stimulation, no theatre admission required.

Once in place, the scaffold supports what is described as matrix-induced chondrogenesis. ChondroFiller contains no cells of its own; it provides a structured matrix into which the patient's own progenitor cells, present in the surrounding joint environment, can migrate and begin repair activity. The mechanism works from the joint surface downward — a 'top-down' approach that contrasts with AMIC's 'bottom-up' process of driving marrow-derived cells upward through microfractured subchondral bone. The two procedures address the same biology from opposite directions, which is why patient selection rather than a simple hierarchy determines which pathway is appropriate.

Candidates for the injection pathway typically include patients with focal defects who cannot or prefer not to undergo surgery, and those with more diffuse or early-to-moderate cartilage wear for whom an operating-theatre procedure would be disproportionate. External published data on ChondroFiller applied arthroscopically in 26 hip patients with FAI-related lesions showed good or excellent results in 17 of 21 at three to five years; poor results clustered in those who already had Tönnis grade 2–3 osteoarthritis — a boundary consistent with both techniques' shared contraindication in established joint degeneration.

Standard defect-size guidance places the injection indication at up to approximately 3 cm², extendable to around 6 cm² in certain cases, which overlaps meaningfully with AMIC's treatment range and is part of why the two can be considered alternatives for some patients.

What the evidence shows for each

AMIC carries the stronger evidence base of the two. A 2025 systematic review and meta-analysis of 628 hips across 12 studies recorded a pooled success rate of 99.6% and a mean improvement in the modified Harris Hip Score (mHHS) of 35.8 points. A 2024 systematic review of 209 hips found 0% conversion to total hip arthroplasty in all AMIC groups at follow-up periods ranging from one to eight years, compared with conversion rates of 2–32.6% in matched microfracture-alone cohorts. Mid-term data at a mean of 6.2 years in a smaller series confirmed sustained Oxford Hip Score and COMI gains with no THA conversions. In a separate comparative cohort of 111 patients, AMIC combined with bone marrow aspirate concentrate achieved 100% survivorship at 18 months versus 67.4% for microfracture alone.

For ChondroFiller, the published hip data needs to be framed honestly before any figures are presented: the available cohort studies involved arthroscopic implantation of the gel in a theatre setting, not the ultrasound-guided outpatient injection that constitutes the current service pathway. That arthroscopic cohort — 26 hip patients with FAI-related lesions — showed good or excellent results in 17 of 21 patients at three to five years, with 92.3% survival recorded in a 2023 systematic review. These figures offer meaningful early signal on the collagen scaffold's performance in the hip environment, but they do not directly measure the outpatient injection route. The injection pathway is supported by the same mechanism rationale — matrix-induced chondrogenesis via a Type I collagen scaffold — alongside broader multi-joint evidence; hip-injection–specific long-term data continues to develop.

No head-to-head randomised trial comparing AMIC surgery to ChondroFiller injection in the hip exists. Because the two procedures also serve partly different patient groups — bordered focal defects suitable for marrow stimulation versus broader or surgery-unsuitable presentations — a direct numerical comparison would in any case be difficult to interpret with confidence.

Recovery:what each pathway realistically involves

The two pathways differ substantially in recovery demand, and that difference is worth factoring in before committing to either route.

AMIC is a surgical procedure, and its post-operative phase reflects that. For the first six weeks, weightbearing is typically restricted to partial loading — crutches are standard — progressing to full weightbearing as the scaffold and marrow-derived cells consolidate within the defect. A structured physiotherapy programme begins early and runs for months, targeting hip strength, movement patterns, and the underlying mechanics that often contribute to FAI-related cartilage damage. Return to low-impact daily activity commonly occurs somewhere between three and six months; return to sport, where relevant, generally falls in the nine-to-twelve-month range depending on defect size and location. These timelines exist because the repair tissue needs time to mature and integrate — compressing that window carries genuine risk to the result.

ChondroFiller injection, as an outpatient procedure performed under local anaesthesia, carries no equivalent operative recovery phase. Patients leave the clinic on the same day. There is no mandatory weightbearing restriction protocol, no surgeon-supervised rehabilitation schedule tied to scaffold maturation, and no prolonged absence from work or daily routine for most patients. Activity guidance is provided, but the overall burden is substantially lower — directly relevant for patients who cannot take extended time away from work, who have caring responsibilities, or who are managing other health conditions alongside their hip problem.

Neither pathway removes the value of hip-focused physiotherapy. Even after a ChondroFiller injection, addressing movement patterns, hip stability, and any underlying FAI-related mechanics remains worthwhile — the injection addresses the defect, not the forces acting on it.

How the right option is identified

The choice between AMIC surgery and ChondroFiller injection rests first on defect characteristics, then on the patient's own circumstances and preferences.

A focal, clearly bordered chondral defect of 2 cm² or more, with healthy surrounding cartilage and preserved joint space (Tönnis grade 0–1), in a patient fit for general or spinal anaesthesia, is the structural profile that points toward AMIC as the restorative surgical option. Where that same focal profile is present but the patient prefers or requires a non-surgical route — or where defect characteristics are better suited to an injectable collagen scaffold — ChondroFiller injection is the relevant pathway to discuss. Established osteoarthritis at Tönnis grade ≥2 closes both options as cartilage-repair strategies; at that stage the appropriate conversation moves toward joint preservation or replacement, not defect repair.

Reaching that determination requires a structured assessment. Weight-bearing X-rays establish Tönnis grade and overall joint space. MRI or CT arthrogram characterises defect depth, size, and subchondral bone condition, and confirms whether the surrounding cartilage is healthy enough to support either technique. Clinical examination adds information about hip mechanics, range of movement, and any FAI-related features that may have contributed to the defect in the first place.

The decision itself is a shared one, weighing defect type, age, activity goals, surgical fitness, and recovery capacity against what each pathway realistically offers. Patients can arrange a hip assessment at Lincolnshire Hip without needing a GP referral, as the service accepts self-referrals directly.

1. [1] Mid-term results of autologous matrix-induced chondrogenesis for large chondral defects in hips with femoroacetabular impingement syndrome. (2024). https://doi.org/10.1302/0301-620X.106B5.BJJ-2023-0864.R1 https://doi.org/10.1302/0301-620X.106B5.BJJ-2023-0864.R1
2. [2] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
3. [3] Autologous Matrix-Induced Chondrogenesis for the Treatment of Hip Acetabular Chondral Lesions Demonstrates Improved Outcomes: A Systematic Review. (2024). https://doi.org/10.1016/j.arthro.2024.04.028 https://doi.org/10.1016/j.arthro.2024.04.028
4. [4] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] A systematic review of surgical methods to restore articular cartilage in the hip. (2018). https://doi.org/10.1302/2046-3758.75.BJR-2017-0331 https://doi.org/10.1302/2046-3758.75.BJR-2017-0331
6. [6] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
7. [7] Autologous matrix-induced chondrogenesis and bone marrow aspirate concentrate compared with microfracture for arthroscopic treatment of femoroacetabular impingement and chondral lesions of the hip. (2020). https://doi.org/10.1093/jhps/hnaa047 https://doi.org/10.1093/jhps/hnaa047
8. [8] Arthroscopic Treatment of Acetabular Cartilage Lesions in Cam-Type Hip Impingement with Membrane Induced Chondrogenesis versus Microfracturing. (2016). https://doi.org/10.17265/2332-7839/2016.01.002 https://doi.org/10.17265/2332-7839/2016.01.002